{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Prism Medico & Pharmacy Ltd
Why is Prism Medico falling/rising?
On 03-Dec, Prism Medico & Pharmacy Ltd witnessed a notable decline in its share price, falling by 4.98% to close at ₹17.19. This downturn reflects a continuation of recent negative trends and underperformance relative to broader market benchmarks.
Prism Medico & Pharmacy Faces Intense Selling Pressure Amid Consecutive Losses
Prism Medico & Pharmacy Ltd has encountered significant selling pressure, with the stock registering a sharp decline and exhibiting a complete absence of buyers on the trading day. This distress selling signals heightened market caution surrounding the company’s near-term prospects.
Prism Medico & Pharmacy Faces Intense Selling Pressure Amid Consecutive Losses
Prism Medico & Pharmacy Ltd has encountered significant selling pressure, with the stock registering a sharp decline of 4.96% today and exhibiting no buying interest. This distress selling comes amid a series of consecutive losses, signalling heightened investor caution in the Non Banking Financial Company (NBFC) sector.
Prism Medico & Pharmacy Faces Intense Selling Pressure Amid Consecutive Losses
Prism Medico & Pharmacy Ltd is currently experiencing significant selling pressure, with the stock registering only sell orders and no buyers in the queue. This distress selling has resulted in a continuation of losses, reflecting a challenging phase for the company within the Non Banking Financial Company (NBFC) sector.
Prism Medico & Pharmacy Faces Intense Selling Pressure Amid Consecutive Losses
Prism Medico & Pharmacy Ltd is experiencing severe selling pressure, with the stock registering a lower circuit and an absence of buyers on the trading day. The company’s shares have recorded consecutive losses across multiple time frames, signalling distress selling and a challenging market environment for this Non Banking Financial Company (NBFC).
Is Prism Medico overvalued or undervalued?
As of November 18, 2025, Prism Medico is fairly valued with a PE ratio of 19.52, significantly lower than peers like Max Healthcare and Apollo Hospitals, but has underperformed the Sensex with a stock return of -24.32% over the past year.
Prism Medico & Pharmacy Q2 2025 Financial Trend Shows Flat Performance Amid Sector Challenges
Prism Medico & Pharmacy, a player in the Non Banking Financial Company (NBFC) sector, reported a flat financial trend for the quarter ending September 2025, marking a shift from its previous positive trajectory. The company’s financial trend score declined to -3 from 7 over the past three months, reflecting a period of subdued operational performance despite a modest rise in profit after tax (PAT) over the last six months.
Prism Medico & Pharmacy's Valuation Upgrade Highlights Financial Challenges and Market Positioning
Prism Medico & Pharmacy, a microcap in the NBFC sector, has experienced a valuation adjustment, now classified as very attractive. Key financial metrics include a PE ratio of 18.90, a Price to Book Value of 0.76, and an ROE of 4.04%, despite challenges in debt servicing and stock performance.
Is Prism Medico overvalued or undervalued?
As of November 17, 2025, Prism Medico is considered undervalued with a valuation grade of very attractive, featuring a PE ratio of 18.90, an EV to EBIT of 11.46, and a Price to Book Value of 0.76, making it a more appealing investment compared to its peers like Apollo Hospitals and Max Healthcare, despite a year-to-date return of -21.45% against the Sensex's 8.72%.
Prism Medico's Valuation Grade Change Signals Competitive Position Amid Market Challenges
Prism Medico & Pharmacy, a microcap in the NBFC sector, has adjusted its valuation, showcasing a PE ratio of 18.90 and an EV to EBITDA ratio of 11.46. Its price-to-book value of 0.76 indicates favorable asset valuation, despite a year-to-date stock decline of 21.45%.
How has been the historical performance of Prism Medico?
Prism Medico experienced significant growth in net sales, rising from 5.28 Cr in Mar'17 to 54.73 Cr in Mar'19, but faced profitability challenges with a declining operating profit margin and a negative profit before tax in Mar'19. Total assets increased to 21.13 Cr, alongside rising liabilities, while cash flow remained stagnant with no reported activity.
Prism Medico & Pharmacy Ltd Faces Selling Pressure with 4.97% Decline Amid Ongoing Losses
Prism Medico & Pharmacy Ltd is experiencing significant selling pressure, marked by consecutive losses and underperformance compared to the Sensex. The stock has declined notably over various time frames, including a year-to-date drop and a substantial five-year decrease, contrasting sharply with the broader market's gains.
How has been the historical performance of Prism Medico?
Prism Medico experienced significant revenue growth from 5.28 Cr in March 2017 to 54.73 Cr in March 2019, but struggled with profitability, reporting a profit before tax of -0.10 Cr in March 2019. Total expenditures rose sharply, leading to a declining operating profit margin of 0.73%, while total assets and liabilities both increased to 21.13 Cr, indicating potential liquidity challenges.
When is the next results date for Prism Medico?
The next results date for Prism Medico is 14 November 2025.
Prism Medico & Pharmacy Ltd Surges 4.97%, Outpacing Sensex Amid Notable Buying Activity
Prism Medico & Pharmacy Ltd is experiencing notable buying activity, with a significant rise today following two days of declines. Over the past three months, the stock has increased substantially, contrasting with its one-year performance. It has shown strong gains over three years, outperforming the Sensex.
Why is Prism Medico falling/rising?
As of 30-Oct, Prism Medico & Pharmacy Ltd's stock price is at 19.50, down 3.61%, and has underperformed its sector and the benchmark Sensex significantly over the past week and month. Despite a rise in investor participation, the stock has shown a consistent downward trend with a year-to-date decline of 19.42%.
Prism Medico & Pharmacy Ltd Faces Significant Selling Pressure with 4.98% Daily Decline
Prism Medico & Pharmacy Ltd is experiencing notable selling pressure, with consecutive losses and a significant decline in today's trading session. Over the past week and month, the stock has underperformed compared to the Sensex. Despite a recent three-month gain, longer-term performance shows substantial declines against the index.
Why is Prism Medico falling/rising?
As of 17-Oct, Prism Medico & Pharmacy Ltd is currently priced at 21.25, reflecting a 4.78% increase today, despite a year-to-date decline of 12.19%. The stock has shown strong long-term performance with a 78.42% return over the past three years, outperforming the Sensex.
Prism Medico & Pharmacy Ltd Rises 4.78%, Surges 23.55% Over Past Month Amid Market Shift
Prism Medico & Pharmacy Ltd is experiencing notable buying activity, with a significant rise today following two days of declines. The stock has gained 23.55% over the past month, outperforming the Sensex. Despite a negative year-to-date performance, it has appreciated 78.42% over three years.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
